Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy
Menée in vitro et à l'aide de xénogreffes, cette étude évalue la faisabilité de combiner deux technologies, à base de cellules souches pluripotentes induites et de récepteurs d'antigènes chimériques, pour disposer à volonté de lymphocytes T ciblés sur CD19
Progress in adoptive T-cell therapy for cancer and infectious diseases is hampered by the lack of readily available, antigen-specific, human T lymphocytes. Pluripotent stem cells could provide an unlimited source of T lymphocytes, but the therapeutic potential of human pluripotent stem cell–derived lymphoid cells generated to date remains uncertain. Here we combine induced pluripotent stem cell (iPSC) and chimeric antigen receptor (CAR) technologies to generate human T cells targeted to CD19, an antigen expressed by malignant B cells, in tissue culture. These iPSC-derived, CAR-expressing T cells display a phenotype resembling that of innate
γδ T cells. Similar to CAR-transduced, peripheral blood γδ T cells, the iPSC
–derived T cells potently inhibit tumor growth in a xenograft model. This approach of generating therapeutic human T cells 'in the dish' may be useful for cancer immunotherapy and other medical applications.